Literature DB >> 15166541

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector.

Stefan Kostense1, Wouter Koudstaal, Mieke Sprangers, Gerrit Jan Weverling, Germaine Penders, Niels Helmus, Ronald Vogels, Margreet Bakker, Ben Berkhout, Menzo Havenga, Jaap Goudsmit.   

Abstract

The seroprevalence of adenovirus types 5 (Ad5) and 35 (Ad35) was investigated in patients at risk of AIDS. The seroprevalence of Ad5 was higher than Ad35 in HIV-infected patients from The Netherlands (60% versus 7%) and sub-Saharan Africa (90% versus 20%). The seroprevalence was similar among HIV-infected and uninfected individuals, and remained constant during progression to AIDS. Ad35 is less prone to neutralization than Ad5, encouraging the further development of Ad35 for vaccination against HIV.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15166541     DOI： 10.1097/00002030-200405210-00019

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  74 in total

Review 1.  Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.

Authors:  Neetu Singh; Aseem Pandey; Suresh K Mittal
Journal:  Expert Rev Mol Med       Date:  2010-04-29       Impact factor: 5.600

2.  Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.

Authors:  Angelique A C Lemckert; Shawn M Sumida; Lennart Holterman; Ronald Vogels; Diana M Truitt; Diana M Lynch; Anjali Nanda; Bonnie A Ewald; Darci A Gorgone; Michelle A Lifton; Jaap Goudsmit; Menzo J E Havenga; Dan H Barouch
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  HIV-1 vaccine development: progress and prospects.

Authors:  Anna R Thorner; Dan H Barouch
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

4.  Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa.

Authors:  Anna R Thorner; Ronald Vogels; Jorn Kaspers; Gerrit J Weverling; Lennart Holterman; Angelique A C Lemckert; Athmanundh Dilraj; Lisa M McNally; Prakash M Jeena; Soren Jepsen; Peter Abbink; Anjali Nanda; Patricia E Swanson; Andrew T Bates; Kara L O'Brien; Menzo J E Havenga; Jaap Goudsmit; Dan H Barouch
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

Review 5.  Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".

Authors:  Kimberly A Schoenly; David B Weiner
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

6.  Type I interferon-dependent activation of NK cells by rAd28 or rAd35, but not rAd5, leads to loss of vector-insert expression.

Authors:  Matthew J Johnson; Niklas K Björkström; Constantinos Petrovas; Frank Liang; Jason G D Gall; Karin Loré; Richard A Koup
Journal:  Vaccine       Date:  2013-12-08       Impact factor: 3.641

7.  Longitudinal quantification of adenovirus neutralizing responses in Zambian mother-infant pairs: Impact of HIV-1 infection and its treatment.

Authors:  Sara R Privatt; Brianna L Bullard; Eric A Weaver; Charles Wood; John T West
Journal:  Vaccine       Date:  2019-08-01       Impact factor: 3.641

Review 8.  Lentiviral vectors for immune cells targeting.

Authors:  Steven Froelich; April Tai; Pin Wang
Journal:  Immunopharmacol Immunotoxicol       Date:  2010-06       Impact factor: 2.730

Review 9.  New insights on adenovirus as vaccine vectors.

Authors:  Marcio O Lasaro; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2009-06-09       Impact factor: 11.454

10.  Chimeric alphavirus vaccine candidates protect mice from intranasal challenge with western equine encephalitis virus.

Authors:  Svetlana Atasheva; Eryu Wang; A Paige Adams; Kenneth S Plante; Sai Ni; Katherine Taylor; Mary E Miller; Ilya Frolov; Scott C Weaver
Journal:  Vaccine       Date:  2009-05-27       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.